Amgen, Inc. (NASDAQ:AMGN) Shares Purchased by Perigon Wealth Management LLC

Perigon Wealth Management LLC boosted its holdings in Amgen, Inc. (NASDAQ:AMGN) by 21.7% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 2,702 shares of the medical research company’s stock after buying an additional 482 shares during the period. Perigon Wealth Management LLC’s holdings in Amgen were worth $637,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Guggenheim Capital LLC lifted its position in shares of Amgen by 10.0% during the fourth quarter. Guggenheim Capital LLC now owns 332,540 shares of the medical research company’s stock worth $80,166,000 after purchasing an additional 30,153 shares in the last quarter. Macquarie Group Ltd. grew its position in shares of Amgen by 5.7% in the 4th quarter. Macquarie Group Ltd. now owns 292,067 shares of the medical research company’s stock worth $70,408,000 after acquiring an additional 15,808 shares in the last quarter. Fulton Bank N.A. lifted its holdings in shares of Amgen by 1.1% in the 1st quarter. Fulton Bank N.A. now owns 17,337 shares of the medical research company’s stock worth $3,515,000 after purchasing an additional 193 shares during the last quarter. RDA Financial Network increased its position in Amgen by 5.0% in the first quarter. RDA Financial Network now owns 4,742 shares of the medical research company’s stock worth $961,000 after buying an additional 225 shares during the period. Finally, American National Bank boosted its holdings in shares of Amgen by 8.7% during the first quarter. American National Bank now owns 27,964 shares of the medical research company’s stock valued at $5,669,000 after acquiring an additional 2,233 shares during the period. 75.73% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director Ronald D. Sugar sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $228.54, for a total transaction of $228,540.00. Following the sale, the director now directly owns 16,576 shares in the company, valued at $3,788,279.04. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $237.31, for a total value of $100,856.75. Following the completion of the transaction, the director now owns 5,834 shares of the company’s stock, valued at $1,384,466.54. The disclosure for this sale can be found here. Over the last three months, insiders sold 3,425 shares of company stock valued at $818,457. Insiders own 0.36% of the company’s stock.

A number of equities analysts recently issued reports on AMGN shares. Royal Bank of Canada decreased their price objective on Amgen from $236.00 to $223.00 and set a “sector perform” rating for the company in a report on Wednesday. Oppenheimer boosted their price target on shares of Amgen from $252.00 to $265.00 and gave the stock an “outperform” rating in a research report on Monday, July 20th. Guggenheim initiated coverage on shares of Amgen in a report on Wednesday, April 15th. They issued a “neutral” rating and a $225.00 price objective for the company. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $240.00 target price for the company in a research report on Wednesday, April 15th. Finally, SunTrust Banks boosted their price objective on Amgen from $254.00 to $268.00 and gave the stock a “buy” rating in a research note on Thursday. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eighteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $253.15.

AMGN opened at $244.67 on Friday. The company has a debt-to-equity ratio of 3.20, a quick ratio of 1.28 and a current ratio of 2.18. The company has a market cap of $144.79 billion, a PE ratio of 19.99, a price-to-earnings-growth ratio of 2.09 and a beta of 0.94. The stock has a 50-day moving average of $244.08 and a 200-day moving average of $227.31. Amgen, Inc. has a 52-week low of $177.05 and a 52-week high of $264.97.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $4.25 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.81 by $0.44. The business had revenue of $6.21 billion during the quarter, compared to analysts’ expectations of $6.19 billion. Amgen had a net margin of 30.04% and a return on equity of 91.98%. Amgen’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the previous year, the company earned $3.97 earnings per share. On average, research analysts predict that Amgen, Inc. will post 15.62 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Monday, August 17th will be paid a dividend of $1.60 per share. This represents a $6.40 annualized dividend and a yield of 2.62%. The ex-dividend date is Friday, August 14th. Amgen’s payout ratio is currently 43.18%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Further Reading: What Are Treasury Bonds?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.